32 results about "Basophilia" patented technology

Blood cells of interest are readily distinguishable from other blood cells and look-a-like particles found in a blood sample by their back-scatter signature. A preferred method for differentiating platelets in a blood sample is to irradiate the cells and particles, one at a time, with a beam of radiation, and to detect back-scattered (reflected) radiation using a plurality of optical fibers to transmit the back-scattered radiation to a high-gain photodetector, e.g. a photomultiplier tube. Preferably, the back-scatter signal so obtained is combined with a second signal representing, for example, either the level of forward-scatter within a prescribed, relatively narrow angular range, or the level of side-scattered radiation, or the level of attenuation of the cell-irradiating beam caused by the presence of the irradiated cell or particle in the beam, or the electrical impedance of the irradiated cell or particle, to differentiate the cells of interest. The method and apparatus of the invention are particularly useful in differentiating platelets and basophils in a blood sample.

The invention belongs to the field of papermaking and discloses pectobacterium carotovorum and applications thereof in bio-pulping. The pectobacterium carotovorum subsp. carotovorum C519 is preserved in China General Microbiological Culture Collection Center with a preservation number is CGMCC No. 3350. The strain can grow under the condition of high alkalinity (pH11), is suitable for degumming process of plant bast fibers and can be used for biological paper pulp. The C519 (CGMCC No. 3350) can grow under an alkaline condition (pH9 to pH 11), and secretes basophilia pectin with high activities (an appropriate pH value is between 8 and 10). Other general microorganisms are difficult to grow and breed in the range of alkalinity, so that the strain can avoid being polluted by other competitors. Moreover, cellulose has no activities under the alkaline condition, thus the strain greatly keeps the original performance of the bast fibers and improves yield.

The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., FcεR1) and an IgG inhibitory receptor (e.g., FcγRIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.

The invention discloses a preparation method of an exosome released by activated basophil. The preparation method comprises the steps of preparing basophil from anticoagulant peripheral blood of a normal person by a negative selection method, performing activation through Anti-IgE stimulation, performing culture in an incubator containing 5% of CO2 at 37 DEG C through serum-free culture mediums for 12-48 hours, then collecting supernatant of cell culture fluid, performing centrifuging under the condition of 300g at room temperature, collecting culture fluid supernatant after the centrifuging,and performing ultracentrifugation so as to obtain the exosome released by activated basophil. The invention also discloses a whole-transcriptome expression profile of the exosome, and a constructionmethod of the whole-transcriptome expression profile. According to the preparation method disclosed by the invention, the exosome released by human basophil is successfully separated and identified for the first time, besides, the whole-transcriptome expression profile of the exosome released by the human basophil is built for the first time, a plurality of RNAs having difference expression afteractivation are identified, and a new target point is provided for further researching a molecular mechanism that the activated basophil acts with target cells during disease generation.

The invention discloses a basophilia mimic enzyme as well as a preparation method and application thereof. The preparation method comprises the following steps: pre-mixing a melamine aqueous solutionand a palladium salt aqueous solution, enabling melamine molecules to be combined with palladium ions by virtue of an electrostatic acting force, adding a reducing agent, stirring, and generating basophilia melamine protective nanopalladium, thus obtaining the basophilia mimic enzyme. The preparation method disclosed by the invention is simple in synthetic condition, low in price of raw materialsand easy in commercial development. The prepared basophilia mimic enzyme has good peroxidase activity under the extreme alkaline pH condition; and moreover, the dispersity in water is good, and the application prospect in the field such as pollutant treatment, detection under the extreme alkaline condition and the like is good.

A method of treating a disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in a subject in need thereof is provided. The method comprising: (a) culturing basophils in the presence of IL33 and/or GM-SCF; and (b) administering to the subject a therapeutically effective amount of the basophils following the culturing, thereby treating the disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in the subject.

The present invention provides cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol,a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceuticalcompositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

The invention uses high-concentration pectin as a unique carbon source to screen an alkaline-resisting bacillus strain from soil; the strain is named Bacillus alcalophilus M29, the preservation date is January 6th, 2009, the full name of the preservation institution is China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 209006; the invention further relates to pectase produced by alkaline-resisting Bacillus alcalophilus M29, having better thermal stability (45 to 65 DEG C), substrate tolerance and basophilia (8.5 to 11, the optimum pH value being 10) and belonging to heat-resisting basophilia pectase; and the invention also relates to the application of the alkaline-resisting Bacillus alcalophilus M29 strain in fermentation and preparation of pectase.

The invention provides a liquid path system which comprises a liquid path of a pretreatment module, a liquid path of a reagent 1 input module, a liquid path of a reagent 2 input module, a liquid pathof a reagent 3 input module and a liquid path of a detection device cleaning module, wherein pipelines for detecting and analyzing lymphocytes, mononuclear cells, neutrophils, eosinophils and basophils are the same pipeline, the liquid path system is simplified, later installation and maintenance are facilitated, a solvent preheating device is added into the liquid path system, the reaction between reagents and samples can be accelerated, meanwhile, the invention also provides a hematology analyzer comprising the liquid path system, and the hematology analyzer is small in size.

The invention belongs to the field of research and development of medicines and health products, and particularly relates to an application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products. The present invention provides the application of NADH and/or NADPH in the antiallergic drugs and/or the antiallergic health products. In the present invention, NADH/NADPH can be administrated to induce Treg cells to secrete immunosuppressive cytokines IL10, TGF-beta and the like. which can inhibit the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgEsynthesis, and increases sIgG and sIgA synthesis, and alleviates allergy symptoms; can stimulate the allergen-specific TH1 response, produces cytokines IFN-gamma and TGF-gamma, inhibits the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgE synthesis and increases sIgG and sIgA synthesis, and alleviates allergy symptoms. The application solves the technical defects thatthe anti-allergic drugs have some adverse reactions, need repeated medication and allergic recurrence, and provides a long-acting, immunomodulatory natural anti-allergic drug or health care product.

The invention relates to the technical field of in vitro diagnosis, and discloses a leukocyte classification reagent. The leukocyte classification reagent comprises a polyoxyethylene type nonionic surfactant, a polyol type nonionic surfactant, a buffer solution, a conductivity supplement, an osmotic pressure regulator and a preservative. The reagent provided by the invention is simple in formula and dye-free, the main components only comprise two specific nonionic surfactants, and the defects of excessive cell damage or too small size and too large distribution span of the same kind of cells and failure in effective classification which are possibly caused by other reagents are avoided. According to the present invention, with the reagent, leukocytes can be divided into monocytes, lymphocytes, neutrophils (including basophils) and eosinophils with clear boundaries, and juvenile granulocytes can be classified.

The invention discloses a skin epidermis repairing material and a preparation method thereof. The skin epidermis repairing material is mainly prepared from, by mass, 12-30 parts of keratin, 13-25 parts of eleidin, 8-25 parts of basophilia keratohyalin granules, 1-8 parts of melanin grains, 12-30 parts of glycosaminoglycans, 8-25 parts of hyaluronic acid, 6-26 parts of chitosan, 1-9 parts of fibronectin and 30-55 parts of deionized water. Compared with the prior art, the skin epidermis repairing material and the preparation method thereof have the advantages that by means of the prepared skin epidermis repairing material, the clinical requirements can be met, high fusion performance with human epidermis is achieved, and regeneration of the skin epidermis can be rapidly facilitated; in addition, toxic and side effects do not occur, use is safe, and healthy hidden troubles do not exist.

The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.

The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.